Details of the Drug

General Information of Drug (ID: DM23UQ9)

• Drug Name: ABT-122

Indication

Disease Entry	ICD 11	Status	REF
Psoriatic arthritis	FA21	Phase 2	[1]
Rheumatoid arthritis	FA20	Phase 2	[2]

• Drug Type: Monoclonal antibody
• Cross-matching ID: TTD ID: D0OX5H
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-17 (IL17)	TTG0MT6	IL17_HUMAN	Modulator	[3]
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Modulator	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02349451) A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate. U.S. National Institutes of Health.
• [3] DOI: 10.1136/annrheumdis-2015-eular.4042